We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-7.45%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$549M
AUM Growth
-$91.5M
Cap. Flow
-$50.6M
Cap. Flow %
-9.22%
Top 10 Hldgs %
42.34%
Holding
105
New
18
Increased
27
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$9.69M
2
CYTK icon
Cytokinetics
CYTK
+$7.79M
3
AMD icon
Advanced Micro Devices
AMD
+$5.25M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.87M
5
PMN icon
ProMIS Neurosciences
PMN
+$4.77M

Top Sells

Rank Stock Value
1
NICE icon
Nice
NICE
+$9.95M
2
NVMI
Nova
NVMI
+$8.21M
3
CAMT icon
Camtek
CAMT
+$6.75M
4
SAGE
Sage Therapeutics
SAGE
+$6.02M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.29M

Sector Composition

Rank Sector Weight
1 Healthcare 60.67%
2 Technology 7.83%
3 Consumer Discretionary 2.21%
4 Communication Services 0.83%
5 Materials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
51
GSK
GSK
$104B
$3.63M 0.66%
100,000
– –
MIRM icon
52
Mirum Pharmaceuticals
MIRM
$6.46B
$3.61M 0.66%
+114,284
New +$3.13M
AMLX icon
53
Amylyx Pharmaceuticals
AMLX
$2.26B
$3.55M 0.65%
193,650
+93,650
+94% +$1.98M
FUSN
54
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$3.52M 0.64%
1,354,258
+25,000
+2% +$80.2K
REPL icon
55
Replimune Group
REPL
$941M
$3.17M 0.58%
+185,016
New +$3.63M
GILD icon
56
Gilead Sciences
GILD
$162B
$3M 0.55%
40,000
– –
PFE icon
57
Pfizer
PFE
$143B
$2.99M 0.54%
90,000
-50,000
-36% -$1.77M
XENE icon
58
PUT
Xenon Pharmaceuticals
XENE
$6.06B
$2.81M 0.51%
+82,400
New +$3.08M
CLDX icon
59
CALL
Celldex Therapeutics
CLDX
$2.99B
$2.75M 0.5%
+100,000
New +$3.13M
PLRX icon
60
Pliant Therapeutics
PLRX
$64.4M
$2.71M 0.49%
+156,134
New +$2.71M
ICL icon
61
ICL Group
ICL
$6.53B
$2.61M 0.48%
+470,000
New +$2.83M
CRWD icon
62
CrowdStrike
CRWD
$194B
$2.51M 0.46%
+60,000
New +$2.33M
KZR
63
DELISTED
Kezar Life Sciences
KZR
$2.44M 0.44%
205,168
+6,345
+3% +$112K
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.06M 0.38%
90,000
– –
ALPN
65
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.06M 0.38%
180,000
-20,000
-10% -$246K
CYTK icon
66
CALL
Cytokinetics
CYTK
$10.5B
$1.91M 0.35%
+65,000
New +$2.16M
GOSS icon
67
Gossamer Bio
GOSS
$82.9M
$1.61M 0.29%
+1,932,568
New +$2.23M
VERA icon
68
Vera Therapeutics
VERA
$2.3B
$1.44M 0.26%
105,000
– –
HOWL icon
69
Werewolf Therapeutics
HOWL
$17.2M
$1.34M 0.24%
626,810
– –
XENE icon
70
Xenon Pharmaceuticals
XENE
$6.06B
$1.33M 0.24%
+38,959
New +$1.46M
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$681M
$1.33M 0.24%
122,813
– –
RZLT icon
72
Rezolute
RZLT
$454M
$1.32M 0.24%
996,710
-159,187
-14% -$260K
CGEN icon
73
Compugen
CGEN
$222M
$1.23M 0.22%
1,319,239
+89,431
+7% +$98.4K
MDWD icon
74
MediWound
MDWD
$181M
$1.15M 0.21%
108,533
-2,594
-2% -$23.8K
QURE icon
75
uniQure
QURE
$3.03B
$998K 0.18%
148,734
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2023 Portfolio in Review

As of Q3 2023, Sphera Funds Management held 105 positions worth $549M, down 14% from $640M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management withdrew a net $50.6M in Q3 2023, closing 23 positions and reducing 20 holdings. Its most notable exit was Nova, an estimated $8.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Cytokinetics worth $6.89M.

  • Sphera Funds Management's largest Q3 2023 buy was Cytokinetics: 233,933 shares worth $6.89M.
  • Sphera Funds Management added most to Tower Semiconductor in Q3 2023, an estimated $9.69M increase.
  • Sphera Funds Management's biggest Q3 2023 reduction was Nice, cutting an estimated $9.95M.
  • Sphera Funds Management fully exited Nova in Q3 2023, selling an estimated $8.21M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $549M portfolio in Q3 2023.
  • Sphera Funds Management opened 18 new positions and closed 23 in Q3 2023.
  • Sphera Funds Management's portfolio value fell 14% quarter-over-quarter to $549M.

Based on Sphera Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.